Quizartinib
Showing 1 - 25 of 37
Healthy Subjects Trial in Nottingham (Quizartinib diHCl, 14C-Quizartinib solution for infusion)
Completed
- Healthy Subjects
- Quizartinib dihydrochloride
- 14C-Quizartinib solution for infusion
-
Nottingham, United KingdomQuotient Sciences
Apr 15, 2022
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,
Recruiting
- Acute Myeloid Leukemia
- +4 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2023
Healthy Subjects, Drug-drug Interaction, Pharmacokinetics Trial in San Antonio (Efavirenz, Quizartinib)
Completed
- Healthy Subjects
- +3 more
- Efavirenz
- Quizartinib
-
San Antonio, TexasWorldwide Clinical Trials
Jun 3, 2022
Acute Myeloid Leukemia (AML) Trial in Tianjin (Quizartinib)
Completed
- Acute Myeloid Leukemia (AML)
- Quizartinib
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital Chinese Acad
Jul 27, 2022
Acute Myeloid Leukemia Trial (Quizartinib, Treatment according to Physician's Choice, Standard of Care Chemotherapy)
Withdrawn
- Acute Myeloid Leukemia
- Quizartinib
- +2 more
- (no location specified)
May 18, 2022
Leukemia, Myeloid, Acute Trial in United States (CPX-351, Quizartinib)
Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in
Recruiting
- Acute Myeloid Leukemia
- +7 more
- Cladribine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Tumor Trial in Houston (Azacitidine, Quizartinib)
Recruiting
- Chronic Myelomonocytic Leukemia
- +5 more
- Azacitidine
- Quizartinib
-
Houston, TexasM D Anderson Cancer Center
May 23, 2022
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia Trial in Houston
Active, not recruiting
- FLT3 Gene Mutation Negative
- +7 more
- Azacitidine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Nov 16, 2022
Acute Myeloid Leukemia Trial in United States (Quizartinib, Milademetan)
Terminated
- Acute Myeloid Leukemia
- Quizartinib
- Milademetan
-
Los Angeles, California
- +7 more
Mar 14, 2022
Acute Myeloid Leukemia Trial in Worldwide (Quizartinib, Intrathecal (IT) triple chemo prophylaxis, Fludarabine)
Recruiting
- Acute Myeloid Leukemia
- Quizartinib
- +4 more
-
Loma Linda, California
- +36 more
Feb 1, 2023
Acute Myeloid Leukemia Trial in Tokyo (Quizartinib, Cytarabine, Idarubicin)
Completed
- Acute Myeloid Leukemia
- Quizartinib
- +3 more
-
Tokyo, Japan(unnamed)
Jul 26, 2021
Hepatic Impairment, Moderate Impaired Hepatic Function Trial in Miami, Orlando (Quizartinib)
Completed
- Hepatic Impairment
- Moderate Impaired Hepatic Function
- Quizartinib
-
Miami, Florida
- +2 more
Aug 16, 2021
Healthy Subjects, Drug-drug Interaction, Pharmacokinetics Trial in San Antonio (Dabigatran Etexilate Mesylate, Quizartinib)
Completed
- Healthy Subjects
- +3 more
- Dabigatran Etexilate Mesylate
- Quizartinib
-
San Antonio, TexasWorldwide Clinical Trials
Jun 16, 2021
Acute Myeloid Leukemia Trial in Spain (Quizartinib, Fludarabine, Cytarabine)
Active, not recruiting
- Acute Myeloid Leukemia
- Quizartinib
- +4 more
-
Alicante, Spain
- +19 more
Mar 11, 2022
Acute Myeloid Leukemia Trial in Spain (Quizartinib, Placebo oral tablet, Cytarabine)
Active, not recruiting
- Acute Myeloid Leukemia
- Quizartinib
- +3 more
-
Santiago De Compostela, A Coruña, Spain
- +44 more
Jan 20, 2022
Leukemia, Myeloid, Acute, De Novo, Age More 60yr Trial in Spain (Azacitidine, Venetoclax, Quizartinib)
Recruiting
- Leukemia, Myeloid, Acute
- +2 more
- Azacitidine
- +3 more
-
Alcalá De Henares, Spain
- +14 more
May 17, 2021
AML, FLT3-ITD Mutation Trial in Hong Kong (Quizartinib, Omacetaxine Mepesuccinate Injection)
Unknown status
- AML
- FLT3-ITD Mutation
- Quizartinib
- Omacetaxine Mepesuccinate Injection
-
Hong Kong, Hong KongThe University of Hong Kong
Dec 9, 2020
AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed
Recruiting
- AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
- MRD-triggered arm
- Prophylactic Arm
-
Heidelberg, BW, GermanyUniversity Hospital Heidelberg Med5
Jan 4, 2021
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood Trial in United States (AC220, Cytarabine,
Completed
- Lymphoblastic Leukemia, Acute, Childhood
- Myelogenous Leukemia, Acute, Childhood
- AC220
- +3 more
-
Los Angeles, California
- +10 more
Mar 24, 2022
Acute Myeloid Leukemia With Gene Mutations Trial (Quizartinib DiHCl)
No longer available
- Acute Myeloid Leukemia With Gene Mutations
- Quizartinib Dihydrochloride
- (no location specified)
Apr 14, 2020
Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Leukemia Trial in Houston
Recruiting
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- +2 more
- Quizartinib
- Venetoclax
-
Houston, TexasM D Anderson Cancer Center
May 13, 2020
AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)
Not yet recruiting
- AML, Adult
- +4 more
- AzaCITIDine Oral Tablet
- Xospata
-
Amiens, France
- +19 more
Sep 1, 2023